Literature DB >> 10769800

[A case of renal tuberculosis following bacillus Calmette-Guerin instillation therapy for bladder cancer].

N Numao1, S Goto, S Suzuki.   

Abstract

A rare case of histopathologically revealed renal tuberculosis caused by intravesical bacillus Calmette-Guerin (BCG) therapy is reported. A 67-year-old man was admitted complaining of fever and micturition pain. He had been undergoing prophylactic BCG instillation therapy for recurrent superficial bladder tumor. Physical examination was unremarkable. The tuberculin skin test was negative. Mycobacterium tuberculosis (MT) was not demonstrated by acid-fast staining and culture of urine. However, MT was isolated by the polymerase chain reaction method. In the following 7 days, symptoms were dissolved with administration of isoniazid, rifampicin and piperacillin. Two months later, nephroureterectomy was performed because of left renal pelvic tumor. Tuberculomas were also found in the renal parenchyma which showed no MT by Ziehl-Neelsen's method. Anti-tuberculous medication was not given postoperatively. Two months after operation, he is free of disease with normal urine examination and positive tuberculin skin test measuring 12 x 10 mm.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10769800

Source DB:  PubMed          Journal:  Hinyokika Kiyo        ISSN: 0018-1994


  3 in total

1.  Renal Tuberculosis Following Intravesical Bacillus Calmette-Guérin (BCG) Immunotherapy for the Treatment of Bladder Cancer.

Authors:  Senad Bajramovic; Jasmin Alic; Edna Skopljak; Adisa Chikha; Sanela Vesnic; Velda Smajilbegovic; Damir Aganovic
Journal:  Med Arch       Date:  2020-04

Review 2.  Emerging concepts and spectrum of renal injury following Intravesical BCG for non-muscle invasive bladder cancer.

Authors:  Azharuddin Mohammed; Zubair Arastu
Journal:  BMC Urol       Date:  2017-12-06       Impact factor: 2.264

3.  Intravesical Bacillus Calmette-Guérin (BCG) treatment's severe complications: A single institution review of incidence, presentation and treatment outcome.

Authors:  R Waked; J Choucair; N Chehata; E Haddad; G Saliba
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2020-02-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.